Biodefense and Emerging Infectious Diseases

Strategic Plan

NIAID's biodefense research priorities include basic research; genomics research, the expansion of research infrastructure, and the development of new diagnostics, therapies, and vaccines to protect civilians against potential agents of bioterrorism.

The NIAID Strategic Plan for Biodefense Research, 2007 (PDF) continues to focus on basic research and its application to product development, but also represents a shift toward a more flexible, broad spectrum approach.

NIAID’s plan reflects the Institute’s partnerships with the U.S. Department of Health and Human Services Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) and the U.S. Department of Homeland Security.

Research Agendas and Progress Reports

• NIAID Strategic Plan for Biodefense Research - 2007 Update
• NIAID Biodefense Research Agenda for CDC Category A Agents, 2006 Progress Report (PDF)
• NIAID Biodefense Research Agenda for CDC Category A Agents, 2006 Progress Report—Overview and Stories of Discovery (PDF)
• NIAID Biodefense Research Agenda for CDC Category A Agents, Progress Report, August 2003 (PDF)
• NIAID Biodefense Research Agenda for CDC Category A Agents (PDF)
• NIAID Biodefense Research Agenda for Category B and C Priority Pathogens, Progress Report, June 2004
• NIAID Biodefense Research Agenda for Category B and C Priority Pathogens (PDF)

Expert Panel Reports

• NIAID Expert Panel Review on Medical Chemical Defense (PDF)
• NIAID Expert Panel on Botulinum Toxins (PDF)
• NIAID Expert Panel on Botulinum Diagnostics (PDF)
• NIAID Expert Panel on Botulinum Neurotoxins Therapeutics (PDF)

back to top